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ABSTRACT
T cell differentiation is dictated by a combination of T cell receptor (TCR) interaction with an 
antigen-bound major histocompatibility complex (MHC), and co-stimulatory molecules signal. 
The co-stimulatory signal can be positive or negative, and amplifying or diminishing the initial 
signal. However, the secondary co-stimulatory signal is not obligatory and its necessity is dic-
tated, in part, by the stage of T cell development. In the field of transplantation, directing the T 
cell differentiation process can lead to therapeutic possibilities that promote allograft tolerance, 
and hinder unfavorable alloimmune responses. Therefore, understanding the details of T cell 
differentiation process, including the influence of co-stimulatory signals, is of paramount im-
portance. It is important to note there is functional overlap between co-stimulatory molecules. 
It has been observed that some co-stimulatory signals have different effects on different T cell 
subsets. Hence, blockade of a co-stimulatory signal pathway, as part of a therapeutic regimen in 
transplantation, may have far reaching effects beyond the initial therapeutic intent and inhibit 
co-stimulatory signals necessary for desirable regulatory responses. In this review, co-stimula-
tory molecules involved in the differentiation of naïve T cells into T helper 1 (Th1), T helper 2 
(Th2), T helper 17 (Th17), inducible regulatory T cells (iTregs), and T helper 9 (Th9) cells and 
their overlap are discussed.
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INTRODUCTION
C
o-stimulatory pathways act synergis-
tically to provide stimulatory and in-
hibitory signals that in combination 
with the T cell receptor-major histocompat-
ibility complex (TCR-MHC) signal pathway 
activate naïve T cells. Activated naïve T cells 
are called effector cells. The effector cells may 
later develop into effector memory (EM) or 
central memory (CM) cells [1].
The co-stimulatory signals are critical for na-
ïve T cell activation, and it has been shown 
that in the absence of these signals, TCR sig-
nal alone leads to T cell anergy, therefore, 
preventing an effective T cell response and 
promoting tolerance in vitro [2]. Knowledge 
of the co-stimulatory pathways is crucial in 
understanding the T cell immune response. 
The three major families of co-stimulatory 
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molecules are immunoglobulin (Ig) superfam-
ily, tumor necrosis factor-tumor necrosis fac-
tor receptor (TNF-TNFR) superfamily, and T 
cell immunoglobulin and mucin (TIM) super-
family [3-5] (Table 1). This review explores 
the role of co-stimulatory pathways in effector 
T helper cells functional differentiation dur-
ing alloimmune response. 
EFFECTOR T CELLS
T helper cells, commonly identified by the ex-
pression of cluster of differentiation 4 (CD4) 
on their cell surface, are important contribu-
tors to the adaptive immune response. There-
fore, they are key factors in autoimmunity, al-
loimmunity, and allergic reactions. To mount 
an appropriate immune response, T helper 
cells differentiate into various subsets. The 
differentiation process is dictated by a combi-
nation of the primary TCR-specific antigen-
MHC signal and the secondary signals by co-
stimulatory molecules. As a result, T helper 
cells can differentiate into various lineages 
including Th1, Th2, Th17, iTregs, and Th9 
each producing specific sets of cytokines and 
having distinct functionality [3, 4, 6-9] (Fig 
1, Table 2). In addition to the primary and 
secondary signals, the cytokines present also 
play a role in the differentiation decision [10]. 
Furthermore, it has been shown that the af-
finity with which the TCR binds to its spe-
cific antigen and the TCR signal strength are 
also important factors in determining the fate 
of the naïve T helper cells [10, 11]. It is also 
important to note that the differentiation pro-
cess is not a terminal event and different CD4+ 
T cell subsets can mutually differentiate [12]. 
For example, under specific conditions Th17 
and Tregs can interconvert [4, 13].
TH1 CELLS
Th1 cells are the first group of differenti-
ated CD4+ cells identified [14]. Th1 cells are 
mainly considered responsible for alloimmune 
Table 1: T cell lineages with their corresponding transcription factors, the cytokines they produce, their 
physiological functions and potential adverse effects, and the co-stimulatory molecules that can affect their 
activity by either promotion or inhibition of their lineage differentiation. 
Lineage
Transcription 
Factors
Cytokine 
Production
Function/ Adverse Effect Co-stimulatory Molecules
Th1
STAT-1
STAT-4
T-bet
IFN-γ
Lymphotoxin
IL-2
Cellular immunity against 
intracellular pathogens
Viral immunity
Hypersensitivity/
Autoimmunity
CD28; OX40; ICOS; 
CD40L; 4-1BB; TIM-1
TIM-3 (inhibitory); 
CTLA-4 (inhibitory); PD-1 
(inhibitory)
Th2
STAT-5
STAT-6
GATA-3
IRF-4
IL-4
IL-5
IL-6
IL10
IL-13
Humoral immunity/B-cell help
Extracellular parasitic/
helminthic infections
Allergy/Atopy
CD28; OX40; ICOS; TIM-
1; TIM-4; TIM-2
CTLA-4 (inhibitory); PD-
1(inhibitory)
Th17
ROR-T
STAT-3
IRF-4
c-maf
IL-17A
IL-17F
IL-21
IL-22
Mediate responses to 
extracellular bacteria and fungi
Autoimmunity
CD28; ICOS; TIM-1; 
CD40L; OX40
TIM-3 (inhibitory)
Th9
STAT-6
IRF-4
IL-9
IL-10
Helminthic infections
Atopy/Autoimmunity
-
Treg FoxP3
TGF-β
IL-10
IL-35
Regulation/Suppression of the 
immune response/Tolerance
CD28; CTLA-4; PD-1/
PDL-1; TIM-3; GITR; 
CD30
OX40 (inhibitory); TIM-1 
(inhibitory)
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response and allograft rejection in the context 
of transplantation [15, 16].
CD40 ligand (CD40L), also known as CD154, 
is a protein marker and a member of TNF-
TNFR superfamily mainly found on the sur-
face of activated Th1 cells [17]. CD40L is a 
co-stimulatory molecule that upon binding 
to CD40 on the surface of antigen present-
ing cells (APCs) induces the secretion of in-
flammatory cytokines TNF and IL-12 by T 
cells. This, in turn, leads to the activation of 
associated APCs by upregulating the expres-
sion of MHC, CD80, and CD86 in them [18]. 
CD40 expression is also upregulated in mac-
rophages, dendritic cells, and B cells creating 
a positive feedback loop and further intensify-
ing the antigen-specific signaling. Due to the 
central role of CD40L in Th1 lineage activa-
tion, interruption of the CD40-CD40L path-
way leads to inhibition of Th1 inflammatory 
response [19]. Indeed, the use of anti-CD40L 
monoclonal antibodies (mAbs) or CD40L 
knock-out strains has been shown to drasti-
cally improve allograft survival, and prevent 
acute rejection in rodent and primate models 
[20-23]. Anti-CD40L mAbs have been used 
in combination with CTLA-4-Ig therapy and 
donor-specific transfusion, promoting toler-
ance [21, 24]. 
However, the beneficial effects of anti-CD40L 
seems to be counteracted when it is used in 
combination with immunosuppressive agents 
cyclosporine A (CsA), and methylprednisolone 
[25]. This is thought to be due to the down 
Table 2: Co-stimulatory molecules, their known ligands, their protein superfamily, and their expression patterns 
in leukocytes
Co-stimulatory 
Molecule
Ligands Family Expression
CD28
B7-1 (CD80); also binds 
PDL-1
B7-2 (CD86)
IgG - CD28/B7
Constitutive - all naive CD4 & CD8 T 
cell subsets
CTLA-4
B7-1 (CD80)
B7-2 (CD86)
IgG - CD28/B7
Constitutive - Tregs
Inducible - activated T cells
ICOS ICOS-L IgG - CD28/B7 Inducible
PD-1
PDL-1; also binds B7-1
PDL-2
IgG - CD28/B7
Constitutive - Tregs/Tfh
Inducible - activated CD4/CD8, 
activated B cells, NK cells & 
macrophages
CD27 CD70 TNF/TNFR
Constitutive - naive T, B & NK cells
Inducible
CD30 CD30L TNF/TNFR
Constitutive - Tregs
Inducible - activated T effector/
memory
CD40L CD40 TNF/TNFR
Inducible - activated T cells, NK cells, 
eosinophils, platelets
OX40 OX40L TNF/TNFR Inducible - activated T cells
TIM-1
TIM-1
TIM-4
TIM Inducible - activated CD4 & CD8T cells
TIM-2 Semaphorin 4A (Sem4A) TIM Inducible - activated T cells (Th2)
TIM-3 Galectin-9 TIM
Inducible - terminally differentiated 
Th1 cells
TIM-4 TIM-1 TIM APCs
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regulation of CD40L by the above-mentioned 
immunosuppressive agents [25]. On the other 
hand, it has been shown that rapamycin (si-
rolimus) has significant synergy with anti-
CD40L, together leading to indefinite graft 
survival by reducing the frequency of alloreac-
tive IFN-γ secretion and inhibition of chronic 
rejection [26]. 
The use of anti-CD40L antibodies in non-hu-
man primates and phase I clinical trials has 
been unsuccessful leading to high incidence 
of thrombotic complications due to the inter-
ruption of the CD40L signaling in platelets 
[27, 28]. Therefore, more recent efforts have 
focused on developing T cell-specific mono-
clonal anti-CD40L antibodies with promising 
early transplantation results [29]. 
In addition to CD40L, TIM-1 is another cell 
surface marker that is rapidly upregulated 
upon activation of naïve CD4+ T cells [30, 31]. 
Binding of TIM-1 to its ligand, TIM-4, on 
APCs sends a positive co-stimulatory signal 
to T cells [32]. TIM-1 is shown to control the 
differentiation of several Th subsets [33, 34]. 
However, following differentiation, TIM-1 ex-
pression is only maintained in Th2 cells while 
Th1 and Th17 cells cease to express this cell 
surface marker [31, 35]. In a multiple sclerosis 
mouse model, the use of a high affinity agonis-
tic anti-TIM1 mAb led to enhanced Th1 and 
Th17 responses, suggesting that TIM-1 is in-
volved in Th cell differentiation [33]. More-
over, the study of an antagonistic anti-TIM-1 
antibody in fully MHC-mismatched murine 
cardiac transplant models led to improved 
survival, suggesting the inhibition of alloreac-
tive Th1 cells and further confirming the role 
of TIM-1 in T helper cell differentiation [36]. 
Figure 1: Schematic of helper T cell fate. The corresponding transcription factors and cytokines responsible 
for differentiation into T helper 1 (Th1), Th2, Th17, Th9, and iTregs are shown. The subsequent cytokines 
produced by differentiated helper T cells is also indicated.
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In another study, recombinant human TIM-1 
extracellular domain fusion protein (TIM-1-
Fc) was successfully used as an immunosup-
pressive agent to significantly prolong fully 
MHC-mismatched murine cardiac allograft 
survival [32]. In this case, TIM-1-Fc inhib-
ited the differentiation of CD4+ T cells into 
Th1 cells by reducing the AKT and ERK1/2 
phosphorylation in the downstream intracel-
lular signal transduction pathway necessary 
for Th1 activation [32]. Interestingly, by 
downregulating the Th1 response, TIM-1-Fc 
indirectly shifts the balance towards Th2 and 
nTregs, further prolonging allograft survival 
[32]. 
CD152, also known as CTLA-4, is another 
cell surface receptor that is upregulated in ac-
tivated T cells [37]. CTLA-4 is structurally 
related to CD28, a well-studied molecule that 
provides co-stimulatory signals in T cells, and 
binds to the same ligands, B7-1 and B7-2, on 
antigen presenting cells [2].
CTLA-4 binds to CD28 receptors with much 
greater affinity and inhibits the downstream 
Akt pathway, preventing the co-stimulatory 
signal necessary for IL-2 production, and T 
cell growth and proliferation [38, 39]. There-
fore, CTLA-4 has been used in research to 
suppress Th1 and Th2 and inhibit their dif-
ferentiation [40]. Qurenshi demonstrated that 
CTLA-4 expressing cells transendocytose 
and degrade B7-1 and B7-2 from other cells 
[41]. This can be another mechanism by which 
CTLA-4 prevents CD28 ligation and co-stim-
ulatory signal, making it a good candidate for 
immune regulation. 
CTLA-4-Ig, a fusion protein consisting of the 
extracellular CTLA-4 domain and Fc con-
stant portion of IgG1, has been used in com-
bination with tolerance induction by donor 
splenocyte transfusion to effectively prolong 
allograft survival in murine models [42-44]. 
Furthermore, CTLA-4-Ig can be used in 
combination with other immunosuppressants 
such as rapamycin, calcineurin inhibitor, and 
methylprednisolone in rodent transplant mod-
els [26]. It is interesting to note that much of 
what is known about the role of CD28 sig-
naling in transplantation has been obtained 
through studies using CTLA-4-Ig. In human 
transplant recipients, belatacept, a higher af-
finity derivative of CTLA-4-Ig has been ap-
proved. However, some of the initial transplant 
trials have demonstrated complications in the 
form of higher rates of severe acute rejection 
[45]. 
TIM-3 is a cell surface marker present on 
cells of innate and adaptive immune system 
[35, 46, 47]. Galectin-9 is TIM-3 receptor 
found in various cell types including regula-
tory T cells and naïve T helper cells [49]. It 
has been shown that once T helper cells get 
activated and differentiate into Th1 lineage, 
they express TIM-3 [47, 48]. IFN-g leads to 
the upregulation of Galectin-9, which binds to 
TIM-3 to create a negative co-stimulatory sig-
nal promoting Th1 cell death through apopto-
sis and necrosis [49]. As expected, it has been 
shown that TIM-3 blockade accelerates Th1-
mediated autoimmune disease in rodent mod-
els [48]. Similarly, TIM-3 blocks the secretion 
of Th1 and Th17 cytokines in human studies, 
although in this case TIM-3 does not appear 
to induce cell death [50]. We have shown that 
blocking TIM-3 by using RMT3-23 blocking 
antibody accelerates allograft rejection in the 
absence of CD80/86 and CD28 co-stimulatory 
signaling [51]. This is expected as in the ab-
sence of TIM-3 inhibitory signal, allospecific 
CD4+ T cells expand and polarize to Th1 cells 
leading to increased secretion of IL-6, IL-17, 
IFN-g, and Granzyme B cytokines [51].
Programmed death 1 (PD-1) protein with its 
ligand (PDL-1) are involved in inhibitory and 
regulatory pathways that promote peripheral 
tolerance and engraftment [52-54]. It has 
been shown that PDL-1 blockade leads to in-
creased rate of differentiation of alloreactive 
Th1 cells, hence, its therapeutic potential in 
transplantation [53, 55]. Furthermore, B7-1 
surface protein is also able to bind to PDL-1 
to initiate an inhibitory signal pathway [56].
Finally, in addition to CD28 and TIM-1, OX40 
is also a cell surface protein that is known to 
create a positive signal to promote Th1 differ-
entiation and IL-12 and IFN-a proinflamma-
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tory cytokines production [10, 33, 57].
TH2 CELLS
There are opposing views on the role of Th2 
cells in the alloimmune response. While some 
data indicate that Th2 cells are involved in 
the rejection response [58, 59], others suggest 
that they may have a regulatory role [60].
The strength of the TCR signal is essential 
in determining the fate of undifferentiated 
helper T cells. A weak TCR signal in combi-
nation with CD28 co-stimulatory signal pro-
motes IL-4 production and activation of the 
GATA-3 pathway leading to differentiation 
into Th2 cells [10, 61, 62]. On the contrary, a 
strong TCR signal promotes IFN-g produc-
tion and Th1 cell differentiation [10]. As dis-
cussed before, in addition to the main TCR-
MHC signal, co-stimulatory signals also play 
an important role in determining T cell fate 
and differentiation. The use of agonistic anti-
CD28 antibodies in rodent models has led to 
the prolongation of allograft survival [63]. In 
addition, a human-primate chimeric mAb that 
selectively blocks CD28 co-stimulatory sig-
nal has been shown to inhibit both acute and 
chronic rejection in non-human primates [64], 
emphasizing the importance of the co-stimu-
latory signals in the T-cell mediated immune 
response.
OX40 is another co-stimulatory molecule that 
provides the signal for the differentiation of 
naïve T helper cells to Th2 cells. The signal 
initiates the downstream cellular pathway that 
leads to the activation of nuclear factor of ac-
tivated T-cells, cytoplasmic 1 (NFATC1) [65]. 
OX40 acts in concert with CD28 to prompt 
the production of IL-4, a cytokine that in-
duces the differentiation of naïve CD4+ cells 
to Th2 cells [65]. Indeed, in the absence of 
CD28, the Th2 response is weakened and the 
naïve Th0 cells differentiate into Th1 cells due 
to the presence of IFN-a and IL-12 [57, 61]. 
OX40 has also been shown to promote in vi-
tro Th2 differentiation in human naïve T cells, 
although it did not inhibit upregulation of IL-
12 and IFN-g [66]. Similarly, the use of an-
ti-OX40 mAb in a murine cardiac transplant 
model accelerated rejection by both Th1 and 
Th2 responses [67]. The blockade of OX40-
OX40L signaling with anti-OX40L mAb in 
combination with rapamycin resulted in sig-
nificant improvement in rodent allograft sur-
vival compared to rapamycin alone confirm-
ing the role of this molecule in Th2 response 
[68]. In addition, the use of anti-OX40L mAb 
in combination with CD28-B7 blocking anti-
bodies prolongs both cardiac and skin graft 
survival in murine models [68, 69].
Inducible T cell co-stimulator (ICOS) is a cell 
surface protein that is upregulated in acti-
vated T cells upon CD28 co-stimulation, and 
conversely downregulated following CTLA-
4 signaling [70]. Binding of ICOS to its li-
gand, ICOS-L, creates a feedback loop that 
downregulates CD86, the ligand of CD28 and 
CTLA-4 on APCs [70]. It has been shown 
that ICOS is able to provide the necessary co-
stimulatory signals for T cell activation in the 
absence of CD28 and hence, regulates differ-
entiation into Th1, Th2, and Th17 cells [71, 
72, 75, 76]. However, ICOS signaling seems 
to be most crucial in Th2 cell differentiation 
by enhancing the IL-4R signal [73]. ICOS-
deficient patients are also deficient in Th1, 
Th2, Th17, and central memory cells further 
confirming the role of this cell surface immu-
noglobulin in T cell polarization [74]. Simi-
larly, ICOS expression is upregulated in acute 
and chronic allograft rejections [72]. There-
fore, ICOS blockade has been used as a thera-
peutic method to hinder the immune response 
and prolong fully MHC-mismatched murine 
allograft models [71, 72]. The use of ICOS 
blockade at a later time point leads to best 
results in terms of prolonging graft survival 
[71], which is consistent with earlier findings 
that ICOS is only expressed after T cell ac-
tivation. Additionally, STAT-4 knockout mice 
that miss this crucial transcription factor for 
Th1 cell activation still show prolongation of 
graft survival upon administration of ICOS 
blockade, suggesting ICOS effect on Th2 cell 
activation [71]. ICOS blockade can be used in 
concert with CD40L to prevent chronic rejec-
tion [72]. Also, the use of ICOS blockade with 
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a short course of CsA leads to permanent en-
graftment of fully MHC mismatched cardiac 
allografts with normal histology at day 100 
[72].
TIM-1 and TIM-4 signaling is also involved 
in Th1, Th2, and Th17 differentiation path-
ways and proliferation. The specific affinity 
antibody to certain TIM-1 epitopes used as 
well as signal strength dictates TIM-1 role in 
the differentiation decision [33]. For example, 
in experimental autoimmune encephalomyeli-
tis models, the use of a high affinity agonistic 
antibody intensified the severity of the disease 
by promoting Th1 and Th17 responses, while 
a low affinity antibody repressed disease de-
velopment by promoting Th2 response [33]. 
Furthermore,  in vivo allergic responses fol-
lowing exposure to Staphylococcus enterotoxin 
B or cholera toxin and peanut extract lead to 
the upregulation of TIM-4 surface marker on 
intestinal and bone marrow dendritic cells re-
spectively that subsequently lead to Th2 dif-
ferentiation and allergic response [77, 78]. 
However, more data are needed to clarify 
TIM-4 role in transplantation.
Finally, activated murine CD4+ T cells that 
are mainly of the Th2 phenotype express a 
cell surface marker known as TIM-2 [79]. To 
date, TIM-2 has only been found in mice and 
it is hypothesized to be involved in negatively 
regulating Th2 cells during allergic and au-
toimmune responses, with little known about 
their role in transplantation [79].
TH17 CELLS
Th17 cells can trigger the rejection response 
in transplantation independent of Th1 pro-
inflammatory lymphocytes and IL-17A cy-
tokine [80, 81]. However, many studies have 
shown that proinflammatory cytokine, IL-
17A, secreted by cells other than Th17 is a ma-
jor contributor to the rejection response [82]. 
Our group was able to demonstrate that Th17 
cells can mediate acute cardiac rejection and 
vasculopathy in murine transplant models in-
dependent of Th1 [80]. Nevertheless, the role 
of Th17 cells in normal alloimmune response 
directed mainly by Th1 cells is to be deter-
mined.
CD28 co-stimulatory signal is necessary for 
Th17 differentiation, as with any other helper 
T cell subset [17, 76]. This has been confirmed 
by the study showing that the use of anti-CT-
LA-4 and CTLA-4-Ig that respectively, po-
tentiate and block CD28 co-stimulatory sig-
nal, leads to the augmentation or inhibition of 
Th17 differentiation [83]. However, another 
study demonstrated that CTLA-4-Ig blockade 
of CD28 co-stimulation facilitated Th17 dif-
ferentiation in both mouse and human models, 
and CD28 signal activation by its binding to 
anti-CD28 mAbs inhibits the differentiation 
of naïve CD4+ cells into Th17 [51, 84].
Similar to CD28, ICOS is involved in Th17 
cell differentiation as shown both in vivo and 
in vitro [76]. ICOS co-stimulatory signal has 
been shown to prompt IL-17 secretion by 
Th17 cells [76]. Additionally, ICOS signaling 
induces the transcription factor c-Maf which 
enhances IL-21 secretion leading to expansion 
and maintenance of Th17 cells [85].
In murine models, ICOS is not a prerequisite 
for Th17 differentiation; however, it is neces-
sary for maintenance of differentiated Th17 
cells [85]. On the other hand, ICOS co-stim-
ulatory signal is necessary for both differen-
tiation and maintenance of human Th17 cells 
[86]. Indeed, ICOS-deficient patients show 
decreased number of CD4+ effector Th1, Th2, 
and Th17 cells, as well as central memory 
cells [74].
In addition to triggering Th1 and Th2 differ-
entiation, TIM-1 signaling also plays a role in 
Th17 differentiation. This was shown by the 
use of agonistic anti-TIM-1 mAb that trigger 
the downstream TIM-1 signaling pathway 
leading to the conversion of regulatory T cells 
to Th17 cells, and therefore, inhibiting toler-
ance development in islet transplantation mod-
els [34]. Additionally, the use of anti-TIM-1 to 
block TIM-1 signaling leads to tolerance by 
inhibition of IL-17 producing cells in a CD28 
and CD40L-independent manner [87]. 
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TIM-4, another member of the transmem-
brane immunoglobulin and mucin domain 
family, prevents differentiation of naïve T cells 
to Th17 and IL-17 production by differenti-
ated Th17 cells [88]. TIM-3 signaling also 
regulates the immune response leading to al-
lograft tolerance [51]. Blocking TIM-3 by us-
ing RMT3-23 blocking antibody accelerates 
allograft rejection in mouse cardiac transplant 
models independent of CD28 and CD80/CD86 
co-stimulatory signals [51]. This is contribut-
ed to increased rate of differentiation of effec-
tor Th1, Th17, as well as IL-6, IL-17, IFN-g, 
and Granzyme-β-producing cells [51]. Simi-
larly, TIM-3 inhibits secretion of proinflam-
matory cytokines by Th1 and Th17 cells in 
human studies [50].
In addition to the previously discussed role in 
Th1 differentiation, CD40-CD40 ligand path-
way is also involved in Th17 cell differentia-
tion [17]. The CD40-CD40L pathway creates 
the perfect setting for Th17 cell differentiation 
by stimulating IL-6 and transforming growth 
factor beta (TGF-b) secretion by dendritic 
cells and macrophages, respectively [89]. In 
dendritic cells, stimulation of pattern recogni-
tion receptors by autoantigens leads to stimu-
lation of these cells to produce IL-6 during an 
autoimmune response [89]. It has been shown 
that CD40 knockout mice are unable to build 
a normal Th17 response against self-antigens 
and are immune from experimental autoim-
mune encephalomyelitis (EAE) [89]. 
Finally, the effect of OX40 receptor on Th17 
cells is unclear. On the one hand, in vitro stud-
ies suggest that OX40 signaling inhibits Th17 
cell differentiation through increased secre-
tion of IFN-g and IL-4 [90]. However, in vivo 
studies show that OX40 signaling is required 
for Th17 activity as seen by facilitation of EAE 
and rheumatoid arthritis [91, 92].
TREGS
Natural regulatory T cells (nTregs) are a sub-
population of T cells that are formed in the 
thymus. Alternatively, induced Tregs (iTregs) 
may be generated in the periphery from CD4+ 
cells in the presence of TGF-b [7]. Tregs are 
most commonly characterized by the expres-
sion of forkhead box P3 (FoxP3) transcrip-
tion factor. They are primarily responsible for 
controlling the immune response. Tregs are 
critical to the development and maintenance 
of self-tolerance, and they can eliminate auto-
immune disease. In the context of transplan-
tation, Tregs are vital to the induction and 
maintenance of allograft tolerance.
Mice deficient in CD28 or its ligands have 
a significantly reduced numbers of natural 
Tregs [93-96]. Therefore, CD28 co-stimula-
tory signals appear to be critical to the devel-
opment of nTregs in the thymus [93]. CD28 
co-stimulation also leads to the production of 
IL-2, which can further direct the differentia-
tion of CD4+ T cells into CD4+ CD25+ Tregs 
[97, 98]. On the other hand, high levels of 
CD28 co-stimulation have the opposite effect 
by inhibiting the generation of iTregs and pro-
moting the differentiation of effector T cells 
through intracellular signaling pathways in-
volving lymphocyte-specific protein tyrosine 
kinase (LcK) [99]. 
It has been shown that CD28-deficient mice 
undergo accelerated rejection of single MHC 
class II-mismatched cardiac allografts [96].
This observation has been attributed to an 
increase in the number of Th1 and Th2 effec-
tor T cells and their associated cytokines, and 
a decrease in the number of Tregs [96], sig-
nifying the immunoregulatory role of CD28. 
However, CD28–/– mice show a prolongation of 
cardiac allograft survival in fully MHC-mis-
matched transplant models indicating plas-
ticity in CD28 role in the immune response 
[96, 100]. Although the use of agonistic anti-
CD28 mAb leads to activation and expansion 
of functional Tregs both in vitro and in vivo 
in rodent models, the same therapy had com-
pletely opposite results in human trials result-
ing in massive cytokine production in phase 
I clinical trials of six healthy volunteers after 
administration of agonistic anti-CD28 mAb 
[101-103]. 
As discussed previously, CTLA-4 (CD152) is 
inducibly expressed on T cells and competes 
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with CD28 for interaction with B7.1 and B7.2 
on APCs, providing a negative co-stimulatory 
signal in Th1/Th2 cell differentiation path-
ways. Additionally, CTLA-4 is constitutively 
expressed on Tregs and has a central role in 
regulatory T cells stability and function [2]. 
The effect of the absence of CTLA-4 was 
studied in CTLA-4 deficient mice [2]. In these 
mice, environmental antigens activate CD4+ 
cells irrepressibly, leading to overwhelming 
lymphocyte proliferation and eventually in-
flammation [2]. 
CTLA-4 controls the inflammatory response 
by both intrinsic and extrinsic cell mecha-
nisms. The cell intrinsic mechanism involves 
the inhibition of Erk and Akt phosphorylation 
pathways [104]. However, there are also data 
showing that CTLA-4 exerts its immune in-
hibitory and tolerance inducing effects by ac-
tivating an enzyme called indoleamine 2,3-di-
oxygenase (IDO) after binding to its B7 ligand 
[104]. The cell extrinsic mechanism of regu-
lating immune response in CTLA-4 express-
ing cells involves the binding and trans-endo-
cytosis of B7.1 and B7.2 on APCs; therefore, 
making them unavailable for CD28 interaction 
and eventual immune response activation [41]. 
Belatacept is a mutant, higher affinity form of 
the CTLA-4 immunoglobulin that has been 
approved for use in transplantation [105]. Be-
latacept binds to B7.1 and B7.2, blocking their 
interaction with both CD28 and CTLA-4. As 
a result, belatacept not only inhibits CD28 
signal transduction and activation pathways, 
but also inhibits the CTLA-4 interaction with 
B7 preventing inhibitory cell intrinsic signal-
ing. This might explain the observation of an 
increase in early acute rejection in phase III 
belatacept trials in the group that received the 
treatment [45]. Our group demonstrated this 
dual effect by showing that hCTLA4-Ig in-
hibits natural Tregs generation leading to the 
acceleration of cellular rejection in MHC class 
II mismatched models in naïve mice; however, 
it also prevents rejection in fully MHC-mis-
matched cardiac transplant mice [106]. 
Additionally, Bluestone has shown that a cohort 
of renal transplant patients treated with anti-
IL-2R and belatacept or calcineurin-inhibitor 
therapy experienced a short-term reduction in 
the number of circulating Tregs that can be 
attributed to anti-IL-2R treatment [107]. It 
is also worth mentioning that, in addition to 
CTLA-4, the PD-1–PDL-1 pathway also ex-
erts immune inhibitory effects by blocking the 
Akt phosphorylation and signal transduction 
pathways, and enhancing the phosphatase and 
tensin homolog (PTEN) cell cycle regulator 
leading to differentiation and maintenance of 
CD4+ CD25+ FoxP3+ Tregs [108, 109]. 
TIM-3–Galectin-9 interaction also controls 
regulatory T cell activation. Natural Tregs 
constitutively express TIM-3 as a cell surface 
marker in mouse cardiac transplant models 
[51]. Galectin-9 is universally expressed on 
both naïve helper T cells and non-activated 
regulatory T cells; however, once activated, 
helper T cells down-regulate their Galectin-9 
expression while no significant difference in 
expression is observed in regulatory T cells 
[47, 48]. 
To confirm the role of TIM-3 in regulatory 
T cell activation, TIM-3 has been blocked 
to show a significant decrease in the number 
of allospecific Tregs, as well as a decrease in 
their suppressive capacity, resulting in signifi-
cant decrease in peripheral immune-tolerance 
[47, 48]. Similarly, it has been shown that add-
ing soluble Galectin-9 leads to survival pro-
longation of both skin and cardiac allograft 
models, further confirming the role of TIM-
3–Galectin-9 signal in regulatory T cells 
activation [110, 111]. The prolongation of al-
lograft survival is due to a decrease in Th1 
and Th17 cytokine secretion and proliferation, 
as well as an increase in the number of regula-
tory T cells [111]. 
TIM-1 receptor, on the other hand, is respon-
sible for the differentiation of effector Th1, 
Th2, and Th17 cells, while suppressing the 
differentiation and immunosuppressive func-
tion of Tregs [31, 33, 34]. Indeed, use of anti-
TIM-1 antibody has been shown to prevent 
transplant tolerance in murine islet transplan-
tation models by enhancement and suppres-
sion of the effector and regulatory T cell func-
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tions, respectively [34].
Finally, CD134, also known as OX40, is a re-
ceptor that inhibits TGF-b, a cytokine respon-
sible for the differentiation of CD4+ naïve T 
cells and effector T cells into CD25+ FoxP3+ 
Tregs [112, 113]. In addition, OX40 signal-
ing in Tregs has been shown to decrease their 
immunosuppressive and immunoregulatory 
function [113, 114]. However, studies of OX40 
knockout mice found no difference in Tregs 
number or suppressive function compared to 
the wild type [113]. 
TH9 CELLS
Th9 is a more recently discovered subset of 
T cells. Cytokines, TGF-b, and IL-4 are in-
volved in directing the differentiation into 
Th9 cell line [6, 9]. It is suggested that TGF-
b reprograms Th2 cells to become Th9 [9]. 
Another study shows that, in the presence of 
IL-4, TGF-b induces Th9 rather than Treg 
cell differentiation [6]. Furthermore, the tran-
scription factors IRF-4 and STAT-6 appear 
to be required for Th9 cell differentiation [6, 
115]. Th9 cells produce IL-9 and IL-10 cyto-
kines and promote inflammatory response in 
tissues [6, 9]. Th9 cells are also involved in 
inflammatory responses occurred in asthma 
and autoimmune diseases [115]. However, the 
exact mechanism for Th9 cells differentiation 
and their role in transplantation is still un-
known and awaits further investigation.
CONCLUSIONS
Co-stimulatory molecules are critical compo-
nents of the immune response. Co-stimulatory 
signals often work in concert and many co-
stimulatory pathways are involved in multiple 
cellular signaling, exponentially adding to 
the complexity of T cells fate. Co-stimulatory 
molecules have great potential as therapeutic 
targets in transplantation, given their abil-
ity to alter and dictate the immune response. 
However, because of the complex nature of the 
co-stimulatory signaling, blockade of a co-
stimulatory molecule may have consequences 
beyond the expected therapeutic intervention 
that needs to be taken into consideration in de-
velopment of novel treatments.
REFERENCES
1.  Pepper M, Jenkins MK. Origins of CD4(+) effector 
and central memory T cells. Nat Immunol 2011;12: 
467-71.
2.  Bour-Jordan H, Esensten JH, Martinez-Llordella M, 
et al. Intrinsic and extrinsic control of peripheral 
T-cell tolerance by costimulatory molecules of the 
CD28/ B7 family. Immunol Rev 2011;241: 180-205.
3.  Sharpe AH. Mechanisms of costimulation. Immu-
nol Rev 2009;229:5-11.
4.  Zhou L, Chong MM, Littman DR. Plasticity of CD4+ 
T cell lineage differentiation. Immunity 2009;30: 
646-55.
5.  Li XC, Rothstein DM, Sayegh MH. Costimulatory 
pathways in transplantation: challenges and new 
developments. Immunol Rev 2009;229:271-93.
6.  Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhib-
its TGF-beta-induced Foxp3+ T cells and, together 
with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) ef-
fector T cells. Nat Immunol 2008;9:1347-55.
7.  Chen W, Jin W, Hardegen N, et al. Conversion of 
peripheral CD4+CD25- naive T cells to CD4+CD25+ 
regulatory T cells by TGF-beta induction of tran-
scription factor Foxp3. J Exp Med 2003;198:1875-
86.
8.  Kretschmer K, Apostolou I, Hawiger D, et al. Induc-
ing and expanding regulatory T cell populations by 
foreign antigen. Nat Immunol 2005;6:1219-27.
9.  Veldhoen  M,  Uyttenhove  C,  van  Snick  J,et al. 
Transforming growth factor-beta ‘reprograms’ the 
differentiation of T helper 2 cells and promotes 
an interleukin 9-producing subset. Nat Immunol 
2008;9:1341-6.
10.  Tao  X,  Constant  S,  Jorritsma  P,  Bottomly  K.   
Strength of TCR signal determines the costimula-
tory requirements for Th1 and Th2 CD4+ T cell dif-
ferentiation. J Immunol 1997;159: 5956-63.
11.  Boyton RJ, Altmann DM. Is selection for TCR affin-
ity a factor in cytokine polarization? Trends Immu-
nol 2002;23:526-9.
12.  O’Shea JJ, Paul WE. Mechanisms underlying lin-
eage commitment and plasticity of helper CD4+ T 
cells. Science 2010;327:1098-102.
13.  Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. 
Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Im-
munol 2009;21: 281-5.
14.  Mosmann TR, Cherwinski H, Bond MW, et al. Two 
types of murine helper T cell clone. I. Definition 
according to profiles of lymphokine activities and 
secreted proteins. J Immunol 1986;136:2348-57.
15.  Mariotti J, Foley J, Ryan K, Buxhoeveden N, et al.  
R. Abdoli, N. Najafianwww.ijotm.com    Int J Org Transplant Med 2014; Vol. 5 (3)  107
Graft rejection as a Th1-type process amenable to 
regulation by donor Th2-type cells through an in-
terleukin-4/STAT6 pathway. Blood 2008;112:4765-
75.
16.  Strom TB, Koulmanda M. Recently discovered T 
cell subsets cannot keep their commitments. J Am 
Soc Nephrol: JASN 2009;20: 1677-80.
17.  Zygmunt  B,  Veldhoen  M.  T  helper  cell  differen-
tiation  more  than  just  cytokines.  Adv Immunol 
2011;109: 159-96.
18.  Ford  ML,  Larsen  CP.  Translating  costimulation 
blockade to the clinic: lessons learned from three 
pathways. Immunol Rev 2009;229:294-306.
19.  Hancock WW, Sayegh MH, Zheng XG, et al. Costim-
ulatory function and expression of CD40 ligand, 
CD80, and CD86 in vascularized murine cardiac al-
lograft rejection. Proceedings of the Nat Acad Sci 
USA 1996;93: 13967-72.
20.  Larsen  CP,  Alexander  DZ,  Hollenbaugh  D,  et al. 
CD40-gp39 interactions play a critical role during 
allograft  rejection.  Suppression  of  allograft  re-
jection  by  blockade  of  the  CD40-gp39  pathway. 
Transplantation 1996;61:4-9.
21.  Larsen CP, Elwood ET, Alexander DZ, et al. Long-
term  acceptance  of  skin  and  cardiac  allografts 
after blocking CD40 and CD28 pathways. Nature 
1996;381: 434-8.
22.  Kenyon NS, Fernandez LA, Lehmann R, et al. Long-
term survival and function of intrahepatic islet al-
lografts in baboons treated with humanized anti-
CD154. Diabetes 1999;48:1473-81.
23.  Kirk AD, Burkly LC, Batty DS, et al. Treatment with 
humanized  monoclonal  antibody  against  CD154 
prevents acute renal allograft rejection in nonhu-
man primates. Nature Medicine 1999;5: 686-93.
24.  Durham MM, Bingaman AW, Adams AB, et al. Cut-
ting edge: administration of anti-CD40 ligand and 
donor bone marrow leads to hemopoietic chime-
rism and donor-specific tolerance without cytore-
ductive conditioning. J Immunol 2000;165:1-4.
25.  Smiley ST, Csizmadia V, Gao W, et al. Differential 
effects  of  cyclosporine  A,  methylprednisolone, 
mycophenolate, and rapamycin on CD154 induc-
tion and requirement for NFkappaB: implications 
for tolerance induction. Transplantation 2000;70: 
415-9.
26.  Sho M, Sandner SE, Najafian N, et al. New insights 
into the interactions between T-cell costimulatory 
blockade  and  conventional  immunosuppressive 
drugs. Ann Surg 2002;236:667-75.
27.  Kawai  T,  Andrews  D,  Colvin  RB,  et al. 
Thromboembolic  complications  after  treatment 
with  monoclonal  antibody  against  CD40  ligand. 
Nature Medicine 2000;6:114.
28.  Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. 
Platelet-derived CD40L: the switch-hitting player 
of  cardiovascular  disease.  Circulation 2002;106: 
896-9.
29.  Adams AB, Shirasugi N, Jones TR, et al. Develop-
ment  of  a  chimeric  anti-CD40  monoclonal  anti-
body that synergizes with LEA29Y to prolong islet 
allograft survival. J Immunol 2005;174:542-50.
30.  McIntire JJ, Umetsu SE, Akbari O, et al. Identifica-
tion of Tapr (an airway hyperreactivity regulatory 
locus) and the linked Tim gene family. Nat Immu-
nol 2001;2: 1109-16.
31.  Umetsu SE, Lee WL, McIntire JJ, et al. TIM-1 induc-
es T cell activation and inhibits the development 
of peripheral tolerance. Nat Immunol 2005;6: 447-
54.
32.  Xiao L, Fu ZR, Liu F, et al. Suppression of allograft 
rejection by Tim-1-Fc through cross-linking with a 
novel Tim-1 binding partner on T cells. PloS One 
2011;6: e21697.
33.  Xiao S, Najafian N, Reddy J, et al. Differential en-
gagement of Tim-1 during activation can positively 
or negatively costimulate T cell expansion and ef-
fector function. J Exp Med 2007;204:1691-702.
34.  Degauque N, Mariat C, Kenny J, et al. Immunostim-
ulatory Tim-1-specific antibody deprograms Tregs 
and prevents transplant tolerance in mice. J Clin 
Invest 2008;118:735-41.
35.  Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, 
Umetsu DT. The costimulatory role of TIM mole-
cules. Immunol Rev 2009;229: 259-70.
36.  Ueno T, Habicht A, Clarkson MR, et al. The emerg-
ing role of T cell Ig mucin 1 in alloimmune respons-
es in an experimental mouse transplant model. J 
Clin Invest 2008;118: 742-51.
37.  Alegre ML, Noel PJ, Eisfelder BJ, et al. Regulation 
of surface and intracellular expression of CTLA4 on 
mouse T cells. J Immunol 1996;157: 4762-70.
38.  Paterson AM, Vanguri VK, Sharpe AH. SnapShot: 
B7/CD28 costimulation. Cell 2009;137:974-4 e1.
39.  Walunas TL, Bakker CY, Bluestone JA. CTLA-4 liga-
tion blocks CD28-dependent T cell activation. J Exp 
Med 1996;183:2541-50.
40.  Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 con-
trol over Foxp3+ regulatory T cell function. Science 
2008;322:271-5.
41.  Qureshi  OS,  Zheng  Y,  Nakamura  K,  et al.  Trans-
endocytosis of CD80 and CD86: a molecular basis 
for the cell-extrinsic function of CTLA-4. Science 
2011;332:600-3.
42.  Baliga P, Chavin KD, Qin L, et al. CTLA4Ig prolongs 
allograft survival while suppressing cell-mediated 
immunity. Transplantation 1994;58:1082-90.
43.  Azuma H, Chandraker A, Nadeau K, et al. Blockade 
of T-cell costimulation prevents development of 
experimental chronic renal allograft rejection. Pro-
ceed Nat Acad Sci USA 1996;93:12439-44.
44.  Sayegh MH, Zheng XG, Magee C, et al. Donor anti-
gen is necessary for the prevention of chronic re-
jection in CTLA4Ig-treated murine cardiac allograft 
recipients. Transplantation 1997;64: 1646-50.
T helper cells fate mapping108 Int J Org Transplant Med 2014; Vol. 5 (3)    www.ijotm.com 
45.  Vincenti F, Charpentier B, Vanrenterghem Y, et al.  
A phase III study of belatacept-based immunosup-
pression  regimens  versus  cyclosporine  in  renal 
transplant recipients (BENEFIT study). Am J Trans-
plant 2010;10: 535-46.
46.  Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff 
RH. TIM genes: a family of cell surface phosphati-
dylserine receptors that regulate innate and adap-
tive immunity. Immunol Rev 2010;235:172-89.
47.  Sabatos CA, Chakravarti S, Cha E, et al. Interaction 
of Tim-3 and Tim-3 ligand regulates T helper type 
1 responses and induction of peripheral tolerance. 
Nat Immunol 2003;4: 1102-10.
48.  Sanchez-Fueyo A, Tian J, Picarella D, et al. Tim-3 
inhibits T helper type 1-mediated auto- and allo-
immune responses and promotes immunological 
tolerance. Nat Immunol 2003;4: 1093-101.
49.  Zhu C, Anderson AC, Schubart A, et al. The Tim-3 
ligand galectin-9 negatively regulates T helper type 
1 immunity. Nat Immunol 2005;6:1245-52.
50.  Hastings WD, Anderson DE, Kassam N, et al. TIM-3 
is expressed on activated human CD4+ T cells and 
regulates Th1 and Th17 cytokines. Eur J Immunol 
2009;39:2492-501.
51.  Boenisch O, D’Addio F, Watanabe T, et al. TIM-3: 
a novel regulatory molecule of alloimmune activa-
tion. J Immunol 2010;185:5806-19.
52.  Yang J, Riella LV, Chock S, et al. The novel costimu-
latory programmed death ligand 1/B7.1 pathway 
is functional in inhibiting alloimmune responses in 
vivo. J Immunol 2011;187:1113-9.
53.  Riella LV, Watanabe T, Sage PT, et al. Essential role 
of PDL1 expression on nonhematopoietic donor 
cells in acquired tolerance to vascularized cardiac 
allografts. Am J Transplant 2011;11:832-40.
54.  Ozkaynak  E,  Wang  L,  Goodearl  A,  et al. Pro-
grammed death-1 targeting can promote allograft 
survival. J Immunol 2002;169: 6546-53.
55.  Sandner SE, Clarkson MR, Salama AD, et al. Role 
of  the  programmed  death-1  pathway  in  regula-
tion of alloimmune responses in vivo. J Immunol 
2005;174:3408-15.
56.  Butte MJ, Keir ME, Phamduy TB, et al. Programmed 
death-1 ligand 1 interacts specifically with the B7-1 
costimulatory molecule to inhibit T cell responses. 
Immunity 2007;27: 111-22.
57.  Lane P. Role of OX40 signals in coordinating CD4 
T cell selection, migration, and cytokine differen-
tiation in T helper (Th)1 and Th2 cells. J Exp Med 
2000;191: 201-6.
58.  Tay SS, Plain KM, Bishop GA. Role of IL-4 and Th2 
responses in allograft rejection and tolerance. Cur-
rent opinion in organ transplantation 2009;14:16-
22.
59.  Piccotti JR, Chan SY, VanBuskirk AM, et al. Are Th2 
helper  T  lymphocytes  beneficial,  deleterious,  or 
irrelevant in promoting allograft survival? Trans-
plantation 1997;63:619-24.
R. Abdoli, N. Najafian
60.  Waaga AM, Gasser M, Kist-van Holthe JE, et al. 
Regulatory functions of self-restricted MHC class II 
allopeptide-specific Th2 clones in vivo. J Clin Invest 
2001;107:909-16.
61.  Rulifson IC, Sperling AI, Fields PE, et al. CD28 co-
stimulation promotes the production of Th2 cyto-
kines. J Immunol 1997;158:658-65.
62.  Rodriguez-Palmero M, Hara T, Thumbs A, Hunig 
T. Triggering of T cell proliferation through CD28 
induces  GATA-3  and  promotes  T  helper  type  2 
differentiation in vitro and in vivo. Eur J Immunol 
1999;29:3914-24.
63.  Laskowski IA, Pratschke J, Wilhelm MJ, et al. An-
ti-CD28  monoclonal  antibody  therapy  prevents 
chronic rejection of renal allografts in rats. J Am 
Soc Nephrol: JASN 2002;13:519-27.
64.  Poirier N, Azimzadeh AM, Zhang T, et al. Inducing 
CTLA-4-dependent  immune  regulation  by  selec-
tive  CD28  blockade  promotes  regulatory  T  cells 
in organ transplantation. Sci Transl Med 2010;2: 
17ra0.
65.  So T, Song J, Sugie K, et al. Signals from OX40 regu-
late nuclear factor of activated T cells c1 and T cell 
helper 2 lineage commitment. Proceed Nat Acad 
Sci USA 2006;103:3740-5.
66.  Ohshima Y, Yang LP, Uchiyama T, et al. OX40 co-
stimulation enhances interleukin-4 (IL-4) expres-
sion at priming and promotes the differentiation 
of naive human CD4(+) T cells into high IL-4-pro-
ducing effectors. Blood 1998;92:3338-45.
67.  Burrell BE, Lu G, Li XC, Bishop DK. OX40 costimu-
lation  prevents  allograft  acceptance  induced  by 
CD40-CD40L blockade. J Immunol 2009;182: 379-
90.
68.  Yuan  X,  Salama  AD,  Dong  V,  et al.  The  role  of 
the  CD134-CD134  ligand  costimulatory  path-
way in alloimmune responses in vivo. J Immunol 
2003;170:2949-55.
69.  Demirci  G,  Amanullah  F,  Kewalaramani  R,  et al. 
Critical role of OX40 in CD28 and CD154-indepen-
dent rejection. J Immunol 2004;172: 1691-8.
70.  Salama AD, Yuan X, Nayer A, et al. Interaction be-
tween  ICOS-B7RP1  and  B7-CD28  costimulatory 
pathways in alloimmune responses in vivo. Am J 
Transplant 2003;3:390-5.
71.  Harada H, Salama AD, Sho M, et al. The role of the 
ICOS-B7h T cell costimulatory pathway in trans-
plantation immunity. J Clin Invest 2003;112:234-
43.
72.  Ozkaynak E, Gao W, Shemmeri N, et al. Importance 
of ICOS-B7RP-1 costimulation in acute and chronic 
allograft rejection. Nat Immunol 2001;2:591-6.
73.  Watanabe  M,  Watanabe  S,  Hara  Y,  et al.  ICOS-
mediated costimulation on Th2 differentiation is 
achieved  by  the  enhancement  of  IL-4  receptor-
mediated signaling. J Immunol 2005;174: 1989-96.
74.  Takahashi N, Matsumoto K, Saito H, et al. Impaired 
CD4  and  CD8  effector  function  and  decreased www.ijotm.com    Int J Org Transplant Med 2014; Vol. 5 (3)  109
memory T cell populations in ICOS-deficient pa-
tients. J Immunol 2009;182:5515-27.
75.  Sperling  AI,  Bluestone  JA.  ICOS  costimulation: 
It’s not just for TH2 cells anymore. Nat Immunol 
2001;2: 573-4.
76.  Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 
T cells regulates tissue inflammation by producing 
interleukin 17. Nat Immunol 2005;6:1133-41.
77.  Yang PC, Xing Z, Berin CM, et al. TIM-4 expressed 
by mucosal dendritic cells plays a critical role in 
food antigen-specific Th2 differentiation and intes-
tinal allergy. Gastroenterology 2007;133:1522-33.
78.  Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG 
but not horse ATG promotes expansion of func-
tional CD4+CD25highFOXP3+ regulatory T cells in 
vitro. Blood 2008;111:3675-83.
79.  Chakravarti S, Sabatos CA, Xiao S, et al. Tim-2 regu-
lates T helper type 2 responses and autoimmunity. 
J Exp Med 2005;202:437-44.
80.  Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A 
novel role of CD4 Th17 cells in mediating cardiac 
allograft  rejection  and  vasculopathy.  J Exp Med 
2008;205:3133-44.
81.  Agorogiannis EI, Regateiro FS, Howie D, et al. Th17 
Cells Induce a Distinct Graft Rejection Response 
That  Does  Not  Require  IL-17A.  Am J Transplant 
2012;12:835-45.
82.  Chadha R, Heidt S, Jones ND, Wood KJ. Th17: con-
tributors to allograft rejection and a barrier to the 
induction of transplantation tolerance? Transplan-
tation 2011;91:939-45.
83.  Ying H, Yang L, Qiao G, et al. Cutting edge: CTLA-
4--B7 interaction suppresses Th17 cell differentia-
tion. J Immunol 2010;185:1375-8.
84.  Bouguermouh S, Fortin G, Baba N, et al. CD28 co-
stimulation  down  regulates  Th17  development. 
PloS One 2009;4:e5087.
85.  Bauquet AT, Jin H, Paterson AM, et al. The costimu-
latory molecule ICOS regulates the expression of 
c-Maf and IL-21 in the development of follicular T 
helper cells and TH-17 cells. Nat Immunol 2009;10: 
167-75.
86.  Paulos CM, Carpenito C, Plesa G, et al. The induc-
ible costimulator (ICOS) is critical for the devel-
opment  of  human  T(H)17  cells.  Sci Transl Med 
2010;2:55ra78.
87.  Yuan X, Ansari MJ, D’Addio F, et al. Targeting Tim-1 
to overcome resistance to transplantation toler-
ance mediated by CD8 T17 cells. Proceed Nat Acad 
Sci USA 2009;106: 10734-9.
88.  Cao W, Ryan M, Buckley D, et al. Tim-4 inhibition 
of T-cell activation and T helper type 17 differentia-
tion requires both the immunoglobulin V and mu-
cin domains and occurs via the mitogen-activated 
protein  kinase  pathway.  Immunology 2011;133: 
179-89.
89.  Iezzi G, Sonderegger I, Ampenberger F, et al. CD40-
CD40L  cross-talk  integrates  strong  antigenic  sig-
nals and microbial stimuli to induce development 
of IL-17-producing CD4+ T cells. Proceed Nat Acad 
Sci USA 2009;106: 876-81.
90.  Li J, Li L, Shang X, et al. Negative regulation of IL-
17 production by OX40/OX40L interaction. Cellular 
Immunology 2008;253: 31-7.
91.  Weinberg AD, Wegmann KW, Funatake C, Whitham 
RH. Blocking OX-40/OX-40 ligand interaction in vi-
tro and in vivo leads to decreased T cell function 
and amelioration of experimental allergic enceph-
alomyelitis. J Immunol 1999;162: 1818-26.
92.  Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano 
G, Yoshino S, Yagita H, Okumura K. Contribution 
of  OX40/OX40  ligand  interaction  to  the  patho-
genesis  of  rheumatoid  arthritis.  Eur J Immunol 
2000;30:2815-23.
93.  Tai X, Cowan M, Feigenbaum L, Singer A. CD28 
costimulation of developing thymocytes induces 
Foxp3 expression and regulatory T cell differentia-
tion independently of interleukin 2. Nat Immunol 
2005;6: 152-62.
94.  Tang  Q,  Henriksen  KJ,  Boden  EK,  et al.  Cut-
ting  edge:  CD28  controls  peripheral  homeosta-
sis  of  CD4+CD25+  regulatory  T  cells.  J Immunol 
2003;171:3348-52.
95.  Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 
costimulation is essential for the homeostasis of 
the  CD4+CD25+  immunoregulatory  T  cells  that 
control autoimmune diabetes. Immunity 2000;12: 
431-40.
96.  Yang  J,  Riella  LV,  Boenisch  O,  et al.  Paradoxical 
functions  of  B7:  CD28  costimulation  in  a  MHC 
class II-mismatched cardiac transplant model. Am 
J Transplant 2009;9: 2837-44.
97.  Guo F, Iclozan C, Suh WK, et al. CD28 controls dif-
ferentiation of regulatory T cells from naive CD4 T 
cells. J Immunol 2008;181:2285-91.
98.  Bour-Jordan H, Bluestone JA. Regulating the regu-
lators: costimulatory signals control the homeo-
stasis and function of regulatory T cells. Immunol 
Rev 2009;229: 41-66.
99.  Semple K, Nguyen A, Yu Y, et al. Strong CD28 co-
stimulation suppresses induction of regulatory T 
cells from naive precursors through Lck signaling. 
Blood 2011;117:3096-103.
100. Lakkis FG, Konieczny BT, Saleem S, et al. Blocking 
the CD28-B7 T cell costimulation pathway induces 
long term cardiac allograft acceptance in the ab-
sence of IL-4. J Immunol 1997;158: 2443-8.
101. Beyersdorf N, Gaupp S, Balbach K, et al. Selective 
targeting of regulatory T cells with CD28 super-
agonists  allows  effective  therapy  of  experimen-
tal  autoimmune  encephalomyelitis.  J Exp Med 
2005;202:445-55.
102. Hunig T. Manipulation of regulatory T-cell number 
and function with CD28-specific monoclonal anti-
bodies. Adv Immunol 2007;95:111-48.
103. Suntharalingam G, Perry MR, Ward S, et al. Cytokine 
T helper cells fate mapping110 Int J Org Transplant Med 2014; Vol. 5 (3)    www.ijotm.com 
storm in a phase 1 trial of the anti-CD28 monoclo-
nal antibody TGN1412. NEJM 2006;355:1018-28.
104. Mellor AL, Munn DH. IDO expression by dendritic 
cells:  tolerance  and  tryptophan  catabolism.  Na-
ture reviews. Immunology 2004;4:762-74.
105. Larsen CP, Pearson TC, Adams AB, et al. Rational 
development of LEA29Y (belatacept), a high-affin-
ity variant of CTLA4-Ig with potent immunosup-
pressive properties. Am J Transplant 2005;5: 443-
53.
106. Riella LV, Liu T, Yang J, et al. Deleterious Effect of 
CTLA4-Ig on a Treg-Dependent Transplant Model. 
Am J Transplant 2012;12: 846-55.
107. Bluestone JA, Liu W, Yabu JM,et al. The effect of 
costimulatory and interleukin 2 receptor blockade 
on regulatory T cells in renal transplantation. Am J 
Transplant 2008;8:2086-96.
108. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et 
al. Blockade of programmed death-1 engagement 
accelerates graft-versus-host disease lethality by 
an IFN-gamma-dependent mechanism. J Immunol 
2003;171: 1272-7.
109. Francisco LM, Salinas VH, Brown KE, et al. PD-L1 
regulates  the  development,  maintenance,  and 
function of induced regulatory T cells. J Exp Med 
2009;206:3015-29.
110. Wang F, He W, Yuan J, et al. Activation of Tim-
3-Galectin-9  pathway  improves  survival  of  fully 
allogeneic  skin  grafts.  Transplant Immunology 
2008;19:12-9.
111. He W, Fang Z, Wang F, et al. Galectin-9 significantly 
prolongs the survival of fully mismatched cardiac 
allografts  in  mice.  Transplantation  2009;88:782-
90.
112. So  T, Croft M.  Cutting  edge: OX40 inhibits  TGF-
beta-  and  antigen-driven  conversion  of  naive 
CD4 T cells into CD25+Foxp3+ T cells. J Immunol 
2007;179: 1427-30.
113. Vu MD, Xiao X, Gao W, et al. OX40 costimulation 
turns off Foxp3+ Tregs. Blood 2007;110: 2501-10.
114. Kroemer A, Xiao X, Vu MD, et al. OX40 controls 
functionally different T cell subsets and their resis-
tance to depletion therapy. J Immunol 2007;179: 
5584-91.
115. Staudt V, Bothur E, Klein M, et al. Interferon-reg-
ulatory factor 4 is essential for the developmental 
program of T helper 9 cells. Immunity 33:192-202.
R. Abdoli, N. Najafian